Telmisartan-d3

Telmisartan-d₃ is intended for use as an internal standard for the quantification of telmisartan by GC- or LC-MS. Telmisartan is a nonpeptide angiotensin (AT) II receptor antagonist which selectively and insurmountably inhibits the AT II receptor subtype AT₁ (K_i = 3.7 nM).¹ It also acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), activating the receptor to 25-30% of that produced by the full agonist rosiglitazone .² Through these actions, telmisartan potently reduces blood pressure in various animal models of hypertension, diminishing cardiac hypertrophy, cardiovascular and renal risk, and glomerulosclerosis.^3,4,5

1.Wienen, W., Hauel, N., Van Meel, J.C.A., et al.Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Br. J. Pharmacol.110245-252(1993) 2.Benson, S.C., Pershadsingh, H.A., Ho, C.I., et al.Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activityHypertension43(5)993-1002(2004) 3.McClellan, K.J., and Markham, A.TelmisartanDrugs56(6)1039-1044(1998) 4.Jugdutt, B.I.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyClin. Interv. Aging5403-416(2010) 5.Schmieder, R.E., Bakris, G., and Weir, M.R.Telmisartan in incipient and overt diabetic renal diseaseJ.Nephrol.24(3)263-273(2011)